Christopher R. Cline - 11 Apr 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: TVTX
Reported as of: 11 Apr 2025
Net transaction value: -$631
SEC form: 4
Accepted by SEC: 14 Apr 2025, 18:23:30 UTC
Prior SEC filing: 04 Feb 2025
Next SEC filing: 05 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Christopher R. Cline filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 14 Apr 2025.

Key facts

This page summarizes Christopher R. Cline's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Apr 2025, 18:23.

Change

Previous filing in this sequence was filed on 04 Feb 2025.
Current net transaction value: -$631.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Sale

Transaction value: $631
Shares: -48
Change %: -0.05%
Price: $13.14
Shares after: 89,990
Date: 11 Apr 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.